UPDATE | April 4, 2023

From DCAT Week 2023: Samsung Biologics Investing $1.5 Bn for New Biomanufacturing Facility

  • MAIL

From DCAT Week 2023: Samsung Biologics Investing $1.5 Bn for New Biomanufacturing Facility

 

Samsung Biologics, a CDMO of biologics, is investing KRW 1.9 trillion ($1.46 billion) for a new biomanufacturing facility in South Korea, which will be the first plant of the company’s second Bio Campus and its fifth biomanufacturing plant overall. Kevin Sharp, Vice President and Head of Samsung Biologics America–Sales, outlined the expansion at the DCAT Member Company Announcement Forum held on March 20, 2023, at DCAT Week. 

 

Read more

From DCAT Week 2023: Samsung Biologics Investing $1.5 Bn for New Biomanufacturing Facility

 

Samsung Biologics, a CDMO of biologics, is investing KRW 1.9 trillion ($1.46 billion) for a new biomanufacturing facility in South Korea, which will be the first plant of the company’s second Bio Campus and its fifth biomanufacturing plant overall. Kevin Sharp, Vice President and Head of Samsung Biologics America–Sales, outlined the expansion at the DCAT Member Company Announcement Forum held on March 20, 2023, at DCAT Week. 

 

Read more

  • CDO
  • CGMP
  • ADC
  • Bio Campus
  • IR
  • CMO

Share article

  • MAIL

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Interests
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy required